Fluoropyrimidine is an investigational drug.
There have been 285 clinical trials for Fluoropyrimidine.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 30th 2018.
The most common disease conditions in clinical trials are Colorectal Neoplasms, Stomach Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Eli Lilly and Company, and Hoffmann-La Roche.
There are seven hundred and ninety-nine US patents protecting this investigational drug and seven international patents.